The LRP8 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblastoid cell line. This product features targeted disruption of the LRP8 gene, generating a heterogeneous cell pool ideal for loss-of-function investigations. The polyclonal format preserves population diversity while eliminating the target protein, allowing researchers to assess LRP8-dependent phenotypes without clonal selection artifacts.
Raji cells are a human Burkitt’s lymphoma-derived lymphoblastoid line that is Epstein-Barr virus (EBV) positive and grows in suspension. As a model of B lymphocyte biology and humoral immunity, these cells provide a well-characterized platform for studying signaling pathways, oncogenic mechanisms, and lipid metabolism in a hematopoietic context. Their robust proliferation and ease of genetic manipulation make them suitable for high-throughput screening and functional genomics.
LRP8, also known as apolipoprotein E receptor 2 (ApoER2), serves as a receptor for Reelin and apolipoprotein E (ApoE), mediating endocytosis and signal transduction. Ligand binding triggers Dab1 phosphorylation by Src family kinases, which activates downstream PI3K/AKT and GSK3?? pathways to regulate neuronal migration and synaptic plasticity. LRP8 interacts with VLDLR, NMDA receptor subunits, PSD-95, and APP, and modulates cofilin dynamics and CREB-dependent transcription. Upstream regulators include thrombospondin-1, selenoprotein P, and F-spondin.
Within the Raji B-cell context, LRP8 knockout offers a unique opportunity to dissect its roles beyond the nervous system. B lymphocytes express components of the Reelin and ApoE pathways, suggesting potential functions in immune cell adhesion, migration, and lipid homeostasis. By eliminating LRP8, researchers can scrutinize its contribution to B-cell receptor cross-talk, cytokine signaling, or metabolic reprogramming, thereby extending the understanding of this receptor in cancer and immunology.
This knockout model enables a wide range of biomedical studies. Applications include exploring Reelin/ApoE signaling in immune cells, screening LRP8 modulators for Alzheimer’s or atherosclerosis, and elucidating lipid metabolism in lymphocytes. Representative assays encompass western blotting for LRP8 and phospho-Dab1, Reelin stimulation and signaling analysis, flow cytometry, and functional assays such as cell adhesion, migration, and lipid uptake. Apoptosis assays can probe LRP8’s role in cell survival. For additional information, please contact Ascent Research.
